ETON Stock Overview
A specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Eton Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.66 |
52 Week High | US$5.81 |
52 Week Low | US$2.42 |
Beta | 1.19 |
1 Month Change | 12.62% |
3 Month Change | -18.12% |
1 Year Change | -7.81% |
3 Year Change | -57.34% |
5 Year Change | -54.70% |
Change since IPO | -41.44% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07FDA accepts Eton application for Topiramate for partial seizures
Dec 17Eton Pharmaceuticals announces availability of ALKINDI SPRINKLE in U.S.
Nov 24Shareholder Returns
ETON | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0.3% | 0.5% | -0.2% |
1Y | -7.8% | 17.9% | 28.2% |
Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: ETON underperformed the US Market which returned 27.7% over the past year.
Price Volatility
ETON volatility | |
---|---|
ETON Average Weekly Movement | 8.0% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ETON's share price has been volatile over the past 3 months.
Volatility Over Time: ETON's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 30 | Sean Brynjelsen | www.etonpharma.com |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis.
Eton Pharmaceuticals, Inc. Fundamentals Summary
ETON fundamental statistics | |
---|---|
Market cap | US$92.22m |
Earnings (TTM) | US$913.00k |
Revenue (TTM) | US$34.30m |
103.0x
P/E Ratio2.7x
P/S RatioIs ETON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ETON income statement (TTM) | |
---|---|
Revenue | US$34.30m |
Cost of Revenue | US$11.58m |
Gross Profit | US$22.72m |
Other Expenses | US$21.81m |
Earnings | US$913.00k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.036 |
Gross Margin | 66.24% |
Net Profit Margin | 2.66% |
Debt/Equity Ratio | 32.4% |
How did ETON perform over the long term?
See historical performance and comparison